VANCOUVER, BC, March 21, 2023 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Reid Robison, Chief Clinical Officer of Numinus, has contributed to studies published in four peer-reviewed papers thus far in 2023 for…


Previous articlePsyence Partners with iNGENū for Palliative Care Clinical Trial in Australia
Next articlePT400 – Beckley Retreats: Combining Modern Science, Tradition, and Holistic Wellness